CSTL
Castle Biosciences Inc
NASDAQ: CSTL · HEALTHCARE · DIAGNOSTICS & RESEARCH
$19.83
+3.07% today
Updated 2026-05-08
Market cap
$583.55M
P/E ratio
—
P/S ratio
1.70x
EPS (TTM)
$-0.42
Dividend yield
—
52W range
$15 – $44
Volume
0.4M
WallStSmart proprietary scores
33
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+8.5
Quality
A2.0
Profitability
F6.7
Valuation
B2/9
Piotroski F-Score
Weak
4.3
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →194 stocks currently score above 75
Price targets
Analyst target
$47.25
+138.28%
12-Month target
—
—
Intrinsic (DCF)
$95.32
Margin of safety
+66.07%
0 Strong Buy8 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 4.27 — safe zone
+ 66.07% below intrinsic value
+ Debt/equity 0.08x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Thin margins at -7.02%
- Negative free cash flow $-34.58M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $137.04M | $219.79M | $332.07M | $344.23M | $344.23M |
| Net income | $-67.14M | $-57.47M | $18.25M | $-24.16M | $-14.52M |
| EPS | — | — | — | — | $-0.42 |
| Free cash flow | $-47.29M | $-19.25M | $36.54M | $28.33M | $-34.58M |
| Profit margin | -48.99% | -26.15% | 5.49% | -7.02% | -7.02% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-21 | MAETZOLD, DEREK J | Sale | 550 | — |
| 2026-04-21 | MAETZOLD, DEREK J | Sale | 1,357 | $25.10 |
| 2026-04-21 | MAETZOLD, DEREK J | Sale | 1,153 | $25.10 |
Peer comparison
Smart narrative
Castle Biosciences Inc trades at $19.83. Our Smart Value Score of 33/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 4.27, it sits in the safe zone. TTM revenue stands at $344.23M. with profit margins at -7.02%. Our DCF model estimates intrinsic value at $95.32.
Frequently asked questions
What is Castle Biosciences Inc's stock price?
Castle Biosciences Inc (CSTL) trades at $19.83.
Is Castle Biosciences Inc overvalued?
Smart Value Score 33/100 (Grade F, Strong Sell). DCF value $95.32.
What is the price target of Castle Biosciences Inc (CSTL)?
The analyst target price is $47.25, representing +138.3% upside from the current price of $19.83.
What is the intrinsic value of Castle Biosciences Inc (CSTL)?
Based on our DCF model, intrinsic value is $95.32, a +66.1% margin of safety versus $19.83.
What is Castle Biosciences Inc's revenue?
TTM revenue is $344.23M.
Piotroski F-Score?
2/9 — weak financial health.
Altman Z-Score?
4.27 — safe zone.
Company info
SectorHEALTHCARE
IndustryDIAGNOSTICS & RESEARCH
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio1.70x
ROE-5.21%
Beta1.11
50D MA$25.30
200D MA$28.56
Shares out0.03B
Float0.03B
Short ratio—
Avg volume0.4M
Performance
1 week-22.45%
1 month-17.88%
3 months-41.25%
YTD-50.54%
1 year—
3 years—
5 years—